Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Protocol: Selinexor/daratumumab/dexamethasone for relapsed/refractory multiple myeloma - Altai Oncology
  1. Home /
    2. Altai Protocol Library /
  2. New Protocol: Selinexor/daratumumab/dexamethasone for relapsed/refractory multiple myeloma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Protocol: Selinexor/daratumumab/dexamethasone for relapsed/refractory multiple myeloma

New Protocol: Selinexor/daratumumab/dexamethasone for relapsed/refractory multiple myeloma
Study:
  • Part of open-label Phase I/IIb STOMP – dose escalation and expansion phases
  • MM with >= 3 prior lines of therapy (to include PI and IMiD)
  • Selinexor: Once wkly 100 mg (n=31) and twice wkly 60 mg (n=3) + daratumumab + dex
Efficacy:
  • ORR: 69% (overall), 69% (bortezomib & lenalidomide refractory pts)
  • Two pts with daratumumab-refractory disease had not responded
  • All responses within first cycle
  • Median DoR: 11.4 mos [9.7 mos – NE]
Safety:
  • Grade 3-4 AEs: Neutropenia (27%), thrombocytopenia (47%), anemia (32%), fatigue (18%), hyponatremia (12%), nausea (9%), diarrhea (3%), infusion-related reaction (3%)

eJHaem. 2021;2:56–65.

Gasparetto C, et al. Selinexor, daratumumab, and dexamethasone in patients with

relapsed or refractory multiple myeloma

https://doi.org/10.1002/jha2.122

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More